JP2016503655A5 - - Google Patents

Download PDF

Info

Publication number
JP2016503655A5
JP2016503655A5 JP2015550820A JP2015550820A JP2016503655A5 JP 2016503655 A5 JP2016503655 A5 JP 2016503655A5 JP 2015550820 A JP2015550820 A JP 2015550820A JP 2015550820 A JP2015550820 A JP 2015550820A JP 2016503655 A5 JP2016503655 A5 JP 2016503655A5
Authority
JP
Japan
Prior art keywords
sequence
listeria
residues
polynucleotide
secreted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015550820A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016503655A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/078119 external-priority patent/WO2014106123A1/en
Publication of JP2016503655A publication Critical patent/JP2016503655A/ja
Publication of JP2016503655A5 publication Critical patent/JP2016503655A5/ja
Pending legal-status Critical Current

Links

JP2015550820A 2012-12-27 2013-12-27 リステリアの抗原配列の発現を容易にするシグナルペプチド融合パートナー、ならびにその調製方法およびその使用 Pending JP2016503655A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261746237P 2012-12-27 2012-12-27
US61/746,237 2012-12-27
US201361780744P 2013-03-13 2013-03-13
US61/780,744 2013-03-13
PCT/US2013/078119 WO2014106123A1 (en) 2012-12-27 2013-12-27 Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018074066A Division JP6671408B2 (ja) 2012-12-27 2018-04-06 リステリアの抗原配列の発現を容易にするシグナルペプチド融合パートナー、ならびにその調製方法およびその使用

Publications (2)

Publication Number Publication Date
JP2016503655A JP2016503655A (ja) 2016-02-08
JP2016503655A5 true JP2016503655A5 (enExample) 2017-02-16

Family

ID=51017446

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015550820A Pending JP2016503655A (ja) 2012-12-27 2013-12-27 リステリアの抗原配列の発現を容易にするシグナルペプチド融合パートナー、ならびにその調製方法およびその使用
JP2018074066A Expired - Fee Related JP6671408B2 (ja) 2012-12-27 2018-04-06 リステリアの抗原配列の発現を容易にするシグナルペプチド融合パートナー、ならびにその調製方法およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018074066A Expired - Fee Related JP6671408B2 (ja) 2012-12-27 2018-04-06 リステリアの抗原配列の発現を容易にするシグナルペプチド融合パートナー、ならびにその調製方法およびその使用

Country Status (12)

Country Link
US (2) US9663557B2 (enExample)
EP (1) EP2938627B1 (enExample)
JP (2) JP2016503655A (enExample)
KR (1) KR102160322B1 (enExample)
CN (1) CN104955835B (enExample)
AU (2) AU2013370210B2 (enExample)
BR (1) BR112015015076A2 (enExample)
CA (1) CA2888727A1 (enExample)
EA (1) EA201590397A8 (enExample)
MX (1) MX2015008329A (enExample)
SG (2) SG10201700916SA (enExample)
WO (1) WO2014106123A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US20110129499A1 (en) 2008-05-19 2011-06-02 Paulo Maciag Dual delivery system for heterologous antigens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
WO2012138377A2 (en) 2010-10-01 2012-10-11 Trustees Of The University Of Pennsylvania The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
WO2013138337A1 (en) 2012-03-12 2013-09-19 Advaxis Suppressor cell function inhibition following listeria vaccine treatment
CA2955612C (en) 2014-07-18 2022-05-17 Advaxis, Inc. Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer
WO2016061115A1 (en) 2014-10-13 2016-04-21 Providence Health & Services-Oregon D/B/A Providence Portland Medical Center Bacterial vaccines deficient in the 2-c-methyl-d-erythritol-4-phosphate pathway and methods of preparation and use thereof
KR102763121B1 (ko) 2015-02-06 2025-02-04 내셔널 유니버시티 오브 싱가포르 치료적 면역 세포의 효능의 향상 방법
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
CA2982543A1 (en) 2015-04-13 2016-10-20 Aduro Biotech, Inc. Immunogenic fusion proteins for the treatment of cancer
MX2017013174A (es) * 2015-04-13 2018-04-11 Aduro Biotech Inc Fusiones de variante iii del receptor de factor de crecimiento epidermico-mesotelina y métodos para usar los mismos.
AU2016262823A1 (en) 2015-05-18 2017-12-07 Universita' Degli Studi Di Trento Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof
ES2970865T3 (es) 2015-12-16 2024-05-31 Gritstone Bio Inc Identificación, fabricación y uso de neoantígenos
NZ746112A (en) * 2016-03-18 2023-01-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
NZ752984A (en) 2016-11-22 2026-03-27 Nat Univ Singapore Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
US20190038733A1 (en) 2017-08-10 2019-02-07 National University Of Singapore T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
AU2018336988B2 (en) 2017-09-19 2023-06-22 Advaxis, Inc. Compositions and methods for lyophilization of bacteria or Listeria strains
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
AU2019231783B2 (en) 2018-03-09 2023-11-16 Advaxis, Inc. Compositions and methods for evaluating attenuation and infectivity of Listeria strains
EP3536706A1 (en) 2018-03-09 2019-09-11 BiOMVis Srl Fusion proteins for the outer membrane vesicle (omv) delivery of heterologous polypeptides and immunogenic compositions thereof
US20210239681A1 (en) 2018-04-27 2021-08-05 Advaxis, Inc. Compositions and methods for evaluating potency of listeria-based immunotherapeutics
CN110408634B (zh) 2018-04-27 2021-08-03 苏州若泰医药科技有限公司 一种非整合李斯特菌疫苗及抗肿瘤免疫应答方法
EP3784776A4 (en) 2018-05-23 2022-01-26 National University of Singapore Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies
EP3725371A1 (en) 2019-04-18 2020-10-21 BiOMVis Srl Method for the production of outer membrane vesicles and immunogenic compositions thereof
CN110499324A (zh) * 2019-09-02 2019-11-26 中生康元生物科技(北京)有限公司 一种用于鉴定肿瘤新抗原的细菌表达载体及筛选鉴定肿瘤新抗原的方法
EP4168593A4 (en) 2020-06-23 2024-11-27 The Regents of the University of Colorado, a body corporate METHODS FOR DIAGNOSIS OF RESPIRATORY PATHOGENS AND PREDICTION OF EVOLUTIONS ASSOCIATED WITH COVID-19

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US5571702A (en) 1991-03-29 1996-11-05 Genentech, Inc. Amplification method for detection of human PF4A receptors
IT1262895B (it) 1992-03-02 1996-07-22 Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
US6379943B1 (en) 1999-03-05 2002-04-30 Merck & Co., Inc. High-efficiency Cre/loxp based system for construction of adenovirus vectors
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US8114414B2 (en) 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
WO1997003715A1 (en) 1995-07-21 1997-02-06 The General Hospital Corporation Method and apparatus of enhancing the delivery of a pharmaceutical formulation
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
US6855320B2 (en) 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
AU2001255196A1 (en) * 2000-03-29 2001-10-08 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing immunogenicity of antigens
CA2460014A1 (en) 2000-09-21 2002-03-28 The Regents Of The University Of California Spas-1 cancer antigen
US7794728B2 (en) 2002-05-29 2010-09-14 The Regents Of The University Of California Attenuated Listeria spp. and methods for using the same
CA2492160A1 (en) 2002-07-12 2004-01-22 The Johns Hopkins University Mesothelin vaccines and model systems
EP1682173A4 (en) 2003-10-15 2007-10-31 Medimmune Inc EPHA2 VACCINE ON LISTERIA BASE
US7842289B2 (en) * 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
US7858097B2 (en) 2004-08-13 2010-12-28 The Trustees Of The University Of Pennsylvania Antibiotic resistance free Listeria strains and methods for constructing and using same
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
EP2860253B1 (en) * 2006-03-01 2018-08-01 Aduro Biotech, Inc. Engineered listeria and methods of use thereof
WO2007117371A2 (en) 2006-03-01 2007-10-18 Anza Therapeutics, Inc. Engineered listeria and methods of use thereof
US20080124354A1 (en) 2006-07-10 2008-05-29 Yvonne Paterson Methods for administering tumor vaccines
JP2010534058A (ja) * 2007-04-16 2010-11-04 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 抗生物質耐性のないリステリア菌およびその構築および使用方法
EP2283112B1 (en) * 2008-05-19 2016-10-12 Aduro Biotech Compositions comprising prfa*mutant listeria and methods of use thereof
GB201010389D0 (en) 2010-06-21 2010-08-04 Ist Superiore Sanita Antibody derivatives
SMT201800444T1 (it) 2010-11-17 2018-09-13 Aduro Biotech Inc Metodi e composizioni per indurre una risposta immunitaria contro egfrviii
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
WO2013138337A1 (en) 2012-03-12 2013-09-19 Advaxis Suppressor cell function inhibition following listeria vaccine treatment

Similar Documents

Publication Publication Date Title
JP2016503655A5 (enExample)
JP2014504851A5 (enExample)
JP2009540801A5 (enExample)
JP2014527404A5 (enExample)
HRP20201873T1 (hr) Sredstva i postupci za liječenje hbv-a
JP2017511135A5 (enExample)
JP2017513502A5 (enExample)
JP2009528065A5 (enExample)
JP2016501829A5 (enExample)
JP2014534202A5 (enExample)
JP5740473B2 (ja) ヒトパピローマウイルス変形体及び免疫増強剤を含む子宮頸癌の予防または治療用組成物
JP2019524150A5 (enExample)
ES2443216T3 (es) Proteínas de fusión que comprenden polipéptidos de VPH y péptidos de inmunopotenciación de tratamiento y prevención del cáncer cervicouterino
JP2013501038A5 (enExample)
KR20110045010A (ko) C형 간염의 치료를 위한 조성물 및 방법
JP2013027391A5 (enExample)
RU2017127024A (ru) Герпесвирус с измененным спектром мишеней, содержащий гибридный гликопротеин н
KR20150084033A (ko) 조건적으로 약독화된 박테리아 종 그리고 이의 제조 방법 및 이의 용도
JP2015524413A5 (enExample)
JP2014519817A5 (enExample)
JP2021507712A5 (enExample)
JP2012102105A5 (enExample)
JP2012532626A5 (enExample)
CN105497886A (zh) 乙肝核心抗原病毒样颗粒作为肿瘤治疗性疫苗载体的应用
WO2022127825A1 (zh) 针对新型冠状病毒感染的疫苗组合物